top of page

GERMANY'S MERCK KGAA IN $3.9 BILLION DEAL TO BUY US BIOTECH FIRM SPRINGWORKS

  • NEWS Desk Global
  • Apr 28
  • 1 min read



Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.

The family-controlled company said in a statement on Monday the purchase price of $47 per share in cash represents an equity value of about $3.9 billion, or an enterprise value of $3.4 billion (3 billion euros), when SpringWorks’ cash holdings are deducted.

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page